Abyssinia Biologics

Executive Summary

Abyssinia Biologics is a preclinical-stage biotechnology company headquartered in San Diego, California, focused on developing novel therapeutics for Alzheimer's disease. The company's proprietary approach targets soluble oligomers of amyloid-beta (Aβ), which are considered the most neurotoxic forms of Aβ and are believed to play a central role in early synaptic dysfunction and cognitive decline. Unlike amyloid plaques, these soluble oligomers can impair neuronal communication even at low concentrations and are thought to drive downstream pathologies such as tau dysregulation. By potently and selectively neutralizing these toxic oligomers, Abyssinia aims to halt or slow disease progression at its earliest stages. The company was founded in 2021 and operates in the antibodies, biologics, and diagnostics categories. As a private, preclinical entity, Abyssinia has not yet disclosed its total funding or valuation, and its pipeline remains undisclosed. However, its focus on a well-validated biological target in Alzheimer's positions it as a potentially impactful player in the neurodegenerative disease space, though it faces significant scientific and regulatory hurdles common to early-stage drug development.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement60% success
• Q4 2026Lead Candidate IND-Enabling Studies Initiation50% success
• Q1 2027First Strategic Research Collaboration40% success